The results of large-scale collection of proprietary Chinese medicines are announced!

 On the evening of December 21, the Hubei Provincial Inter-provincial Alliance of Chinese Patent Medicines Central Procurement Leading Group Office issued the "Announcement of the Proposed Selection Results of the Centralized Procurement of Proprietary Chinese Patent Medicines of the Inter-provincial Alliance of Chinese Patent Medicines", that is, Hubei 19 provincial alliances, 17 groups of 76 proprietary Chinese medicines planned The results of the selection were officially announced.
According to the results of the selection, the largest drop was more than 82%, and some drugs were as low as 8 cents per tablet
.
This time, led by Hubei, 19 provinces including Hebei, Shanxi, Inner Mongolia, Liaoning, Fujian, Jiangxi, Henan, Hunan, Hainan, Chongqing, Sichuan, Guizhou, Tibet, Shaanxi, Gansu, Ningxia, Xinjiang, and Xinjiang Production and Construction Corps formed inter-provincial The alliance has jointly carried out centralized procurement of Chinese patent medicines, and carried out centralized procurement of medicines in a normalized and institutionalized manner, gradually expanding coverage, guiding the prices of Chinese patent medicines to a reasonable level, and effectively reducing the burden of medicines on the people
.
On December 21, at the Central Procurement Information Disclosure Conference of the Chinese Patent Medicine Alliance held in Hubei, a total of 157 companies and 182 products from the 17 product groups in the procurement catalog participated
.
Through on-site competition, 97 companies and 111 products were selected, with a selection rate of 62%.
The selected products have complete formulations and specifications, with an average drop of 42.
27% and a maximum drop of 82.
63%
.
According to the calculation of the annual demand of the 19 provincial alliances, it is estimated that more than 2.
6 billion yuan of drug costs can be saved each year
.
The price reduction effect of the centralized procurement of the Chinese Patent Medicine Alliance will radiate to the whole country, and the burden of patients' drug costs is expected to be further reduced
.
It is understood that since the beginning of this year, many places have opened the curtain of centralized procurement of Chinese patent medicines
.
For example, on September 19, Guangdong announced the launch of the collective procurement of the Chinese Patent Medicine Alliance in 7 provinces
.
On September 14, the Guangdong Provincial Drug Trading Center issued the "Guangdong Union Qingkailing and other 58 drug groups' procurement documents (draft for comments)"
.
However, the Hubei Province Inter-provincial Centralized Procurement Alliance of Chinese Patent Medicines is large in scale, which will have a greater impact on the national Chinese patent medicine market.

.
It is reported that the centralized procurement of the proprietary Chinese medicine alliance has many characteristics, such as the formation of an inter-provincial alliance to conduct centralized procurement of mainstream proprietary Chinese medicines with large clinical use and high purchase amount; the price reduction is supplemented by clinical recognition and production and supply capacity.
Comprehensive evaluation and competition on indicators such as innovation ability, drug quality, recruitment credit rating, etc.
have explored new paths for the continuous development of centralized procurement of Chinese patent medicines; medical institutions have a high degree of participation, with a total of more than 24,000 medical institutions in the alliance provinces participating in reporting and so on
.
According to the industry, as local pilot projects for centralized procurement of Chinese patent medicines are carried out in various places, some Chinese patent medicine companies will face pressure to reduce prices
.
The cost of raw materials of Chinese patent medicines is easily affected by natural factors and market fluctuations, and it is difficult to control.
After the collection of Chinese patent medicines, pharmaceutical companies will lower the price of medicines, and the pressure may be greater.
Since now, a large number of Chinese herbal medicines have shown varying degrees.
The price increase trend
.
Therefore, the centralized procurement of Chinese patent medicines is different from the centralized procurement of chemical medicines
.
With the announcement of the results of the Proposed Chinese Patent Medicine Alliance of 19 provinces in Hubei and the advancement of various medical reform policies, the pace of centralized procurement of Chinese patent medicines will continue to accelerate, and the national procurement of Chinese patent medicines may be just around the corner
.
At the same time, some Chinese medicine companies without core competitiveness will also be eliminated by the times.
For example, a Chinese medicine company has sold subsidiaries several times this year to improve cash flow
.